Downloads: 1
| # | Blank 1 | Frequency | Blank 2 | Frequency | Blank 3 | Frequency | |
|---|---|---|---|---|---|---|---|
| 1 | 2 | unable | 2 | unwilling to discontinue use of prohibited | 4 | 3 | |
| 2 | 1 | subject is unable | 1 | unwilling to discontinue predefined prohibited | 2 | listed in the protocol for 4 weeks of a drug whichever is longer prior to visit 1 and for the duration of the study | 2 |
| 3 | 3 | patient is unable | 1 | nonprescription | 1 | for at least 7 days prior to the first dose of study drug and for the duration of the study | 1 |
| 4 | 4 | expansion cohort only patient is unable | 1 | NA | for at least 28 days prior to the first dose of topotecan / pazopanib and for the duration of the study | 1 | |
| 5 | 5 | 1 | NA | NA | |||
| 6 | 7 | subjects who are unable | 1 | NA | NA |